by Virtus | Jun 6, 2026 | Early-Stage Respiratory Drug Development
Asthma drug development plays a critical role in improving outcomes for millions of people living with asthma worldwide. Despite significant advances in treatment, asthma remains a complex and highly variable respiratory disease that continues to drive demand for...
by Virtus | Jun 6, 2026 | Early-Stage Respiratory Drug Development
Respiratory drug development is a complex process that transforms scientific discoveries into therapies for patients with respiratory diseases. From asthma and COPD to viral respiratory infections, developing new respiratory medicines requires a combination of...
by Virtus | May 3, 2026 | Early-Stage Respiratory Drug Development
Respiratory CRO UK vs global CRO is a common comparison for biotech and pharmaceutical companies planning preclinical respiratory studies. Respiratory drug development requires disease-specific expertise, validated models, and reliable in vivo respiratory studies,...
by Virtus | May 3, 2026 | Early-Stage Respiratory Drug Development
Respiratory CRO services support biotech and pharmaceutical companies developing therapies for asthma, COPD, and viral respiratory diseases by delivering specialist preclinical respiratory studies. A respiratory preclinical CRO provides disease-specific models, in...
by Virtus | Apr 11, 2026 | Early-Stage Respiratory Drug Development
Outsourcing vs in-house respiratory research is a common consideration for biotech and pharmaceutical companies developing therapies for asthma, COPD, and viral respiratory diseases. Respiratory drug development requires specialised preclinical models, in vivo...
by Virtus | Apr 11, 2026 | Early-Stage Respiratory Drug Development
Finding the best respiratory CRO in the UK is a key step for biotech and pharmaceutical companies developing therapies for asthma, COPD, and viral respiratory diseases. Respiratory drug development requires specialised preclinical models, in vivo respiratory studies,...
